How Collaboration Is Driving the Next Wave of Genomics

Illumina’s Open Innovation programs work with partners to change lives



Illumina’s advances in genetic sequencing are reshaping medicine. Genetic sequencing has now allowed cancer patients to find treatment options specific to their tumors, doctors to anticipate adverse drug reactions and personalize medicine, public health agencies around the world to track and detect new COVID variants, and patients with rare diseases to more easily identify and treat their illnesses.

Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children

Hannover Medical School study will evaluate the use of whole-genome sequencing to show positive impact of earlier diagnosis and treatment for children with suspected genetic disorders
Press Release

SAN DIEGO, April 25, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced an agreement with Germany's Hannover Medical School (Medizinische Hochschule Hannover (MHH)) to implement the use of whole-genome sequencing (WGS) in critically ill children suspected of having a genetic or rare disease.

Cambridge Launchpad As Illumina Targets Five Million STEM Learners


 By Tony Quested

Cambridge is unveiled as the launchpad for the biggest long-term initiative ever unveiled on this side of the Atlantic to get more youngsters involved in STEM careers – thanks to US genomics giant Illumina.

Illumina and Cambridge LaunchPad joined forces in an historic venture to take the DNA Day programme to UK schools for the first time. Cambridge was chosen for the launch as the founding cradle of DNA discovery and genomics advancements.

World Must Leverage Genomics to Fight Pandemics, Illumina CEO Says



Two years into the pandemic that has killed millions and shaken the global economy, the world still lacks a unified effort to detect and fight future outbreaks using genetic tools, said Illumina Inc. Chief Executive Officer Francis deSouza.

Baby Fitz's Life-Saving Diagnosis Through Whole-Genome Sequencing

How genomics provided critical answers—and in record time—to transform outcomes for a newborn and his family

In June 2019, Christina and Daniel Kettler were barely home from the hospital with their newborn son when they received an urgent phone call. They needed to rush back immediately: A routine screening, called the heel stick test, had revealed that Fitz, their firstborn baby, had Severe Combined Immunodeficiency (SCID). SCID is a rare condition also known as “bubble boy disease.”

Illumina Releases Annual Corporate Social Responsibility Report

Report highlights contributions of genomics to advances in public health and overall health of our planet
Press Release

SAN DIEGO, April 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health. The report details Illumina's role as a champion for patients, communities, people, and the planet.

Illumina and Next Generation Genomic Launch Expanded NIPT in Thailand

The collaboration will introduce VeriSeq™ NIPT Solution v2 in Southeast Asia
Press Release

Over a quarter of the world’s population resides in Southeast Asia, with over 70 million people in Thailand alone. Now, many of the growing families in this region will be able to better prepare for the next stage of their lives, with genomics providing more accurate and accessible data than ever before.

Illumina Corporation Foundation and Discovery Education Inspire Youth to Pursue Careers in STEM and Genomics through New Groundbreaking Program ‘DNA Decoded’

Illumina Corporation Foundation invests in digitally immersive education curriculum program to pave the way for the next generation of genomics professionals
Press Release

SILVER SPRING. Md., February 20, 2019 /3BL Media/ – Illumina Corporate Foundation and Discovery Education, the leading provider of digital curriculum resources, digital content, and professional development for K-12 classrooms, today launched DNA Decoded, a program designed to equip middle and high school teachers with the power to unlock the study of genomics to advance the future for their students.

Cisco’s Virtual Pediatric Network Connects Doctors to Cancer Patients

by Jan Jensen

On January 28, 2015, Cisco launched the Virtual Pediatric Network (VPN) at the Children’s Hospital of Orange County (CHOC) Children’s Hospital Hyundai Cancer Institute in Southern California.

The VPN, a Cisco Corporate Social Responsibility initiative, uses advanced Cisco technology to connect pediatric oncologists, genomic researchers, and bioinformatics experts, allowing them to collaborate closely in treating children with cancer.


Subscribe to genomics